Mitali Sharma’s Post

AstraZeneca's Tagrisso Plus Chemotherapy for Lung Cancer Recommended by CHMP The European Union's CHMP has recommended AstraZeneca's Tagrisso combined with pemetrexed and platinum-based chemotherapy for first-line treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer. This recommendation follows positive results from the Phase III FLAURA2 trial, which showed that the combination therapy extended median progression-free survival by nearly nine months compared to Tagrisso monotherapy and reduced the risk of disease progression or death by 38%. This recommendation marks a significant milestone in NSCLC treatment, providing a new therapeutic option for patients in Europe, and underscores AstraZeneca's commitment to advancing cancer care. For more details please click the link! https://lnkd.in/dnYCmGUc #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical 

At Propanc Biopharma, Inc. (OTCQB:PPCB), we're dedicated to making a difference in the lives of cancer patients. Our mission is to develop groundbreaking therapies that provide hope and improve the quality of life for those affected by pancreatic, ovarian, and colorectal cancers.   Our team of dedicated scientists and oncology consultants have harnessed a century of research on enzyme use to create a novel therapeutic approach. This approach not only addresses metastatic cancer but also aims to significantly reduce recurrence rates.   As a clinical-stage biopharmaceutical company, we're committed to advancing the field of oncology and bringing innovative treatments to patients who need them most. Together, we're making strides in the battle against cancer and striving for a brighter future for cancer patients worldwide.   Join us in our journey towards a world with more effective and long-lasting cancer treatments. Together, we can make a meaningful impact on the lives of those facing these challenging diseases.   https://lnkd.in/gdeCiAip   #CancerResearch #InnovationInOncology #PropancBiopharma #CancerTreatment #SolidTumors #MedicalBreakthroughs #PPCB

European Commission Gives Nod to Initial Ovarian Cancer Therapy The European Commission has approved rucaparib as a first-line maintenance therapy for advanced ovarian cancer patients who have responded well to initial chemotherapy, regardless of their BRCA mutation status. This expands the treatment options for a broader population of patients and offers potential benefits earlier in their treatment. Rucaparib was previously approved as a maintenance therapy for patients with relapsed ovarian cancer. The approval was based on positive outcomes from a Phase III study showing improved progression-free survival compared to a placebo. This approval provides hope for patients in need of better treatment options for advanced ovarian cancer. For more details please click the link! https://lnkd.in/dnbTd_tf #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

💥 Super proud of our participating company OncoDNA, a $30 million project to fight cancer! 👊   🧬 The aim: to develop therapeutic cancer vaccines based on messenger RNA, products that are currently under development. And yes, the secret was well kept!   OncoDNA was selected by the European Commission from a list of 14 projects from five countries to support innovation in the pharmaceutical sector. This selection entitles the project to public investment of €30 million. A family of patents for these treatments has already been filed.   🚀 For our participating company, this represents a paradigm shift, since it's no longer just a question of carrying out biomarker tests to find the right treatment. The team of Jean-Pol Detiffe and Christophe Van Huffel is changing dimension and aims to become a producer of treatments that can all be customised in just a few days. A revolution! We're proud to be part of it!   Read in L'Echo article on OncoDNA's paradigm shift (link in commentary to this post) 👇   #lifesciences #cancer #health #treatment Gery Lefebvre Anne VEREECKE

At Propanc Biopharma, Inc. (OTCQB:PPCB), we're dedicated to making a difference in the lives of cancer patients. Our mission is to develop groundbreaking therapies that provide hope and improve the quality of life for those affected by pancreatic, ovarian, and colorectal cancers.   Our team of dedicated scientists and oncology consultants have harnessed a century of research on enzyme use to create a novel therapeutic approach. This approach not only addresses metastatic cancer but also aims to significantly reduce recurrence rates.   As a clinical-stage biopharmaceutical company, we're committed to advancing the field of oncology and bringing innovative treatments to patients who need them most. Together, we're making strides in the battle against cancer and striving for a brighter future for cancer patients worldwide.   Join us in our journey towards a world with more effective and long-lasting cancer treatments. Together, we can make a meaningful impact on the lives of those facing these challenging diseases.   https://lnkd.in/gZzMGxRN   #CancerResearch #InnovationInOncology #PropancBiopharma #CancerTreatment #SolidTumors #MedicalBreakthroughs #PPCB

A short and sweet article about the combination of ADCs with immune modulators!

Excited to attend the FDA Oncology Center of Excellence (OCE) Conversations on Cancer webinar this afternoon. Discussion will focus on the most transformative oncology drug approvals for 2023, and feature a diverse panel of speakers including patients, advocates, clinical investigators, and practitioners who will address: ☑️Patient and investigator perspectives on their experiences with these drugs, including importance of timely access. ☑️Patient perspectives on the impact of these drugs on their cancer prognosis and quality of life. ☑️Investigators’ perspectives on the impact of these drugs on their respective cancer landscape and treatment paradigm for the specified cancer indication(s).  ☑️Barriers to access of these newly approved drugs and ways to help overcome these barriers. #oncologyresearch #cancerresearch #patientexperience #advocacymatters #drugdevelopment

Treatment for Cervical Cancer KEYTRUDA, Approved by FDA, Combined with Chemoradiotherapy The FDA has approved Merck's anti-PD-1 therapy, KEYTRUDA, in combination with chemoradiotherapy (CRT) for treating patients with advanced cervical cancer. This is the third indication for KEYTRUDA in cervical cancer and the 39th in the U.S. The approval is based on positive results from a clinical trial showing a 41% reduction in the risk of disease progression or death compared to placebo plus CRT. The approval expands treatment options for cervical cancer patients and highlights the potential of immunotherapy in addressing unmet medical needs. For more details please click the link! https://lnkd.in/dBrxe6dh #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

The #LungCancer space has never been busier (IMHO). 📛 From a priority review pathway, the US FDA approves Amgen's tarlatamab/Imdelltra, for use in advanced small cell lung cancer (SCLC), which pluses up ➕ its bispecific T-cell engagers (BiTE). So, what are BiTEs? I like Phil Taylor/pharmaphorum's description: 🔬 "BiTE drugs are designed to engage the immune system against cancer by bringing T-cells and cancer cells into close proximity. In the case of tarlatamab, the molecule binds to CD3 receptors on T-cells and DLL3 on SCLC cells, and it is the first drug in the anti-DLL3 class to be approved for marketing, as well as the first BiTE for a solid tumour." re: the DLL3's: ♣ Other programs in play, namely, from Boehringer Ingelheim (having a fast-tracked asset) and Harpoon Therapeutics (a tri-specific; in prostate cancer studies) Is Lung Cancer or these innovative MOAs/targets an area of particular interest? Contact your team of Life Science Associates at Fletcher to learn more about our solutions, capabilities, and strength of our in-depth studies to support and inform on your strategic priorities! #LungCancer #Oncology #SolidTumor #Innovation #Regulatory #Pharma #Healthcare

Remarkable Progress in Colorectal Cancer Treatment by Opdivo Plus Yervoy Combo Bristol Myers Squibb has announced groundbreaking results from a Phase 3 trial showing that the combination of Opdivo and Yervoy demonstrated a significant reduction in the risk of disease progression or death for patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer. The combination therapy showed an improvement in progression-free survival compared to chemotherapy and had a manageable safety profile. The findings highlight the potential of immunotherapy in revolutionizing the treatment of this type of cancer. The trial is ongoing, with additional endpoints yet to be assessed. For more details please click the link! https://lnkd.in/duDZjW9S #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical